This work aimed to verify whether TMZ, at low and clinically relevant doses (5-20 μM), could induce COX-2 overexpression in GBM cells (T98G and U87MG) and explore if secreted EV shuttled COX-2 to recipient cells. Here, PTGS2 is linked to glioblastoma.